| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | MTND5; ND5 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human MT-ND5 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于FGFR3抗体的3篇文献的简要信息(文献为虚构示例，仅供参考格式)：
1. **文献名称**：*Targeting FGFR3 in bladder cancer with inhibitory antibodies: a novel therapeutic approach*
**作者**：Smith J, et al.
**摘要**：研究开发了一种针对FGFR3的高选择性单克隆抗体，可抑制受体过度激活。在膀胱癌细胞系和小鼠模型中，该抗体显著抑制肿瘤增殖并诱导凋亡，为FGFR3突变型癌症提供了潜在疗法。
2. **文献名称**：*Anti-FGFR3 antibody ameliorates skeletal dysplasia in a mouse model of achondroplasia*
**作者**：Chen L, et al.
**摘要**：通过靶向FGFR3胞外域的抗体阻断其异常信号传导，成功缓解了软骨发育不全小鼠模型的骨骼生长抑制，证实抗体治疗对遗传性骨骼疾病的有效性。
3. **文献名称**：*FGFR3-specific antibody-drug conjugate shows potent antitumor activity in multiple myeloma*
**作者**：Wang H, et al.
**摘要**：设计了一种FGFR3抗体-药物偶联物(ADC)，在表达FGFR3的多发性骨髓瘤临床前模型中表现出强效肿瘤杀伤作用，且对正常组织毒性较低，支持其进入临床试验。
(注：以上文献为示例性内容，实际引用需查询真实数据库如PubMed。)
The fibroblast growth factor receptor 3 (FGFR3) is a transmembrane tyrosine kinase receptor that plays a critical role in regulating cell proliferation, differentiation, and survival. It is part of the FGFR family (FGFR1-4) and is activated by binding to FGF ligands, triggering downstream signaling pathways like MAPK and PI3K-AKT. FGFR3 is particularly important in skeletal development; gain-of-function mutations are linked to genetic disorders such as achondroplasia, while aberrant activation or overexpression is associated with cancers, including bladder cancer, multiple myeloma, and cervical cancer.
FGFR3-targeting antibodies are therapeutic tools designed to inhibit dysregulated signaling. These antibodies typically block ligand binding, prevent receptor dimerization, or suppress kinase activity, thereby curbing tumor growth or mitigating developmental abnormalities. Monoclonal antibodies like vofatamab (B-701) have shown promise in clinical trials for cancers with FGFR3 alterations. Additionally, antibody-drug conjugates (ADCs) and bispecific antibodies are being explored to enhance specificity and efficacy.
Challenges in FGFR3 antibody development include overcoming resistance mechanisms, managing off-target effects, and identifying predictive biomarkers. Despite these hurdles, FGFR3 remains a compelling target due to its central role in both developmental disorders and oncogenesis, driving ongoing research to refine antibody-based therapies.
×
